\
&
Contact us
\
&
Contact us
Starts in 1 week from now
LocationOnline
ProgrammesInnovative Health Initiative (IHI) projects and Innovative Medicines Initaitive (IMI) projects engage cross-sectoral and multidisciplinary approaches to deliver results from cancer diagnosis to cure, and tackle 14 different cancer indications from lung, colorectal, breast and prostate cancer, which are the most commonly diagnosed cancers in the EU, to rarer cancers such as brain and blood cancers which are the most common types of childhood cancer.
To date, IMI and IHI have funded 22 cancer projects to the tune of €480 million of public and private investments addressing various aspects of the prevention, diagnosis and treatment of cancer.
The aim of the event is to explore some of the highlights from several IHI and IMI projects focused on cancer.
More information and registration on the IHI website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
